MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

Rhea-AI Summary

MaxCyte (NASDAQ: MXCT) reported third quarter 2025 results and reiterated full-year 2025 guidance on Nov 12, 2025. Total revenue was $6.8M in Q3 2025, down 16% year-over-year; core revenue was $6.4M, down 21% YoY. Gross profit was $5.2M (77% gross margin); non-GAAP adjusted gross margin was 81% versus 85% in Q3 2024. Q3 net loss was $12.4M; adjusted EBITDA loss improved to $10.0M from $13.0M. Installed instrument base rose to 830. Management reiterated 2025 guidance: core revenue flat to -10% and ~$5M SPL program revenue; expected year-end cash of $152M–$155M.

Positive

• Installed instrument base +12% to 830 units
• Adjusted EBITDA loss improved to a $10.0M loss
• SPL program revenue guidance of approximately $5M for 2025
• Total cash, cash equivalents and investments of $158.0M at Sep 30, 2025

Negative

• Total revenue down 16% year-over-year to $6.8M
• Core revenue down 21% year-over-year to $6.4M
• Licenses revenue declined 29%; PAs/consumables -25%; instruments -22%
• Non-GAAP adjusted gross margin fell 4 percentage points to 81%

Insights

Corporate finance analyst

Mixed quarter: revenue declined materially, margins stay healthy, cash balance strong and guidance unchanged.

MaxCyte reported total revenue of $6.8 million for the quarter, down 16% year‑over‑year, with core revenue down 21%. Gross margin remained robust at 77%, and adjusted gross margin ex‑program items was 81%. The company ended the quarter with $158.0 million in cash and investments.

The business shows three balancing dynamics. First, top‑line contraction in instruments, consumables and licenses drives near‑term revenue weakness. Second, profitability metrics improved modestly: operating expenses fell and adjusted EBITDA loss narrowed to $10.0 million. Third, management announced an operational restructuring to reduce costs and reiterated full year guidance, including SPL program revenue of about $5 million for 2025.

Key dependencies and risks include continued SPL client wins and execution of the restructuring without disrupting commercialization. Watch quarterly trends in core revenue and SPL receipts, the year‑end cash range of $152 million to $155 million, and any update to operating expense trajectory over the next two quarters (near term).

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance.

Third Quarter and Recent Highlights

• Core business revenue of $6.4 million in the third quarter of 2025.
• Strategic Platform License SPL Program-related revenue was $0.4 million for the third quarter of 2025.
• Total revenue of $6.8 million in the third quarter of 2025.
• MaxCyte added one new SPL client, Moonlight Bio, in October, in addition to Adicet Bio and Anocca AB in July. The total number of SPL agreements stands at 32.
• Total cash, cash equivalents and investments were $158.0 million as of September 30, 2025.
  

“We remain on track to achieve our full year 2025 revenue guidance,” said Maher Masoud, President and CEO of MaxCyte. “In the third quarter, we announced an operational restructuring to significantly reduce costs and accelerate our path towards profitability, while strengthening our ability to grow over the long-term. Though the external cell and gene therapy operating environment has rationalized over the last few years, we firmly believe that our value proposition for customers remains strong, as evidenced by recently signing our fourth SPL this year, Moonlight Bio. We remain committed to continued investments in SeQure Dx, product enhancement initiatives, and expanding the breadth of our cell engineering offerings, but will do so with commercial discipline to produce long-term sustainable growth for MaxCyte.”

The following tables provide details regarding the sources of the Company’s revenue for the periods presented.

	Three Months Ended September 30 (Unaudited)
	2025				2024				% Change
(in thousands, except percentages)
Instruments	$	1,376			$	1,764				(22	%)
PAs and consumables		2,577				3,432				(25	%)
Licenses		1,803				2,528				(29	%)
Assay services		248				–				–
Other		402				416				(3	%)
Total Core Revenue	$	6,406			$	8,140				(21	%)
Program-Related		423				24				1,663	%
Total Revenue	$	6,829			$	8,164				(16	%)

In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:

	Three Months Ended September 30,
	2025		2024
Installed base of instruments (sold or leased)	830		739
Core Revenue Generated by SPL Clients as a % of Core Revenue	53	%	53	%

Third Quarter 2025 Financial Results

Total revenue for the third quarter of 2025 was $6.8 million, compared to $8.2 million in the third quarter of 2024, representing a decrease of 16%.

Core business revenue (sales of instruments, PAs and consumables, assay services, and licenses to customers, excluding SPL Program-related revenue) for the third quarter of 2025 was $6.4 million, compared to $8.1 million in the third quarter of 2024, representing a decrease of 21%.

SPL Program-related revenue was $0.4 million in the third quarter of 2025, as compared to immaterial in the third quarter of 2024.

Gross profit for the third quarter of 2025 was $5.2 million (77% gross margin), compared to $6.2 million (76% gross margin) in the third quarter of 2024. Non-GAAP adjusted gross margin was 81% excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 85% in the third quarter of 2024.

Operating expenses for the third quarter of 2025 were $19.4 million, compared to operating expenses of $20.3 million in the third quarter of 2024.

Third quarter 2025 net loss was $12.4 million compared to net loss of $11.6 million for the same period in 2024. Adjusted EBITDA, a non-GAAP measure, was a loss of $10.0 million for the third quarter of 2025, compared to a loss of $13.0 million for the third quarter of 2024; stock-based compensation expense was $2.0 million in the third quarter of 2025 compared to $3.4 million in the third quarter of 2024.

2025 Guidance

MaxCyte reiterates 2025 revenue guidance for core business revenue and SPL Program-related revenue:

• Core revenue is expected to be flat to a 10% decline compared to 2024, inclusive of revenue from SeQure Dx.
• SPL Program-related revenue is expected to be approximately $5 million for the year. SPL-program related revenue guidance includes both expected revenue from pre-commercial milestone payments and commercial royalties/sales-based payments.

MaxCyte expects to end 2025 with $152 million to $155 million in total cash, cash equivalents and investments. Our revised guidance reflects near term cash utilization from the operational restructuring announced on September 22, 2025.

Webcast and Conference Call Details

MaxCyte will host a conference call today, November 12, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

Non-GAAP Financial Measures

This press release contains EBITDA, which is a non-GAAP measure defined as earnings before interest income and expense, taxes, depreciation and amortization. This press release also contains Adjusted EBITDA, which is a non-GAAP measure defined as earnings before interest, taxes, depreciation, amortization and one-time restructuring charges. MaxCyte believes that EBITDA and Adjusted EBITDA provide useful information to management and investors relating to its results of operations. The company’s management uses these non-GAAP measures to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA and Adjusted EBITDA provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.

This press release also contains Non-GAAP Gross Margin, which we define as Gross Margin when excluding SPL program related revenue and reserves for excess and obsolete inventory. The Company believes that the use of Non-GAAP Gross Margin provides an additional tool to investors because it provides consistency and comparability with past financial performance, as Non-GAAP Gross Margin excludes non-core revenues and inventory reserves, which can vary significantly between periods and thus affect comparability.

Management does not consider these Non-GAAP financial measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant revenues and expenses that are required by GAAP to be recorded in the Company’s financial statements. In order to compensate for these limitations, management presents these Non-GAAP financial measures along with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Reconciliation tables of net loss, the most comparable GAAP financial measure, to EBITDA and Adjusted EBITDA, and Gross Margin, the most comparable GAAP financial measure, to Non-GAAP Gross Margin, are included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading “Risk Factors” and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s preliminary results of operations, including fourth quarter and full year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.

These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:

Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

MaxCyte, Inc. Unaudited Consolidated Balance Sheets (in thousands, except share and per share amounts)
	September 30, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$	12,973			$	27,884
Short-term investments, at amortized cost		92,755				126,598
Accounts receivable, net		8,306				4,682
Inventory		7,611				8,914
Prepaid expenses and other current assets		3,000				3,606
Total current assets		124,645				171,684
Investments, non-current, at amortized cost		52,274				35,781
Property and equipment, net		18,620				19,707
Right-of-use asset - operating leases		11,135				10,766
Goodwill		3,554				—
Intangible assets, net		667				—
Other assets		2,581				1,532
Total assets	$	213,476			$	239,470
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	1,286			$	1,358
Accrued expenses and other		8,306				8,302
Operating lease liability, current		1,314				864
Deferred revenue, current portion		5,196				5,251
Total current liabilities		16,102				15,775
Operating lease liability, net of current portion		16,847				17,170
Contingent consideration		25				—
Other liabilities		227				274
Total liabilities		33,201				33,219
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2025 and December 31, 2024		—				—
Common stock, $0.01 par value; 400,000,000 shares authorized, 106,644,343 and 105,711,093 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		1,066				1,057
Additional paid-in capital		431,096				422,047
Accumulated deficit		(251,887	)			(216,853	)
Total stockholders’ equity		180,275				206,251
Total liabilities and stockholders’ equity	$	213,476			$	239,470

MaxCyte, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share amounts)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2025				2024				2025				2024
Revenue	$	6,829			$	8,164			$	25,726			$	29,934
Cost of goods sold		1,596				1,928				4,612				4,819
Gross profit		5,233				6,236				21,114				25,115
Operating expenses:
Research and development		5,316				5,316				17,488				17,613
Sales and marketing		3,936				6,207				15,420				20,188
General and administrative		6,028				7,745				22,634				22,487
Restructuring expense		3,058				-				3,058		-
Depreciation and amortization		1,044				1,021				3,185				3,123
Total operating expenses		19,382				20,289				61,785				63,411
Operating loss		(14,149	)			(14,053	)			(40,671	)			(38,296	)
Other income:
Interest income		1,733				2,496				5,637				7,838
Total other income		1,733				2,496				5,637				7,838
Net loss	$	(12,416	)		$	(11,557	)		$	(35,034	)		$	(30,458	)
Basic and diluted net loss per share	$	(0.12	)		$	(0.11	)		$	(0.33	)		$	(0.29	)
Weighted average shares outstanding, basic and diluted		106,613,075				105,109,603				106,324,792				104,614,679

MaxCyte, Inc. Unaudited Consolidated Statements of Cash Flows (in thousands)
	Nine Months ended September 30,
	2025				2024
Cash flows from operating activities:
Net loss	$	(35,034	)		$	(30,458	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		3,268				3,258
Lease right-of-use asset amortization		587				353
Net book value of consigned equipment sold		70				35
Loss on disposal of property and equipment		132				462
Stock-based compensation		8,507				9,949
Credit loss expense (recovery)		29				(130	)
Change in excess/obsolete inventory reserve		525				834
Amortization of discounts on investments		(2,219	)			(5,052	)
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable		(3,649	)			1,348
Inventory		647				835
Prepaid expense and other current assets		744				(225	)
Other assets		(924	)			(732	)
Accounts payable, accrued expenses and other		(3,338	)			(1,420	)
Operating lease liability		(939	)			(424	)
Deferred revenue		(80	)			1,584
Other liabilities		(47	)			(6	)
Net cash used in operating activities		(31,721	)			(19,789	)
Cash flows from investing activities:
Purchases of investments		(98,031	)			(118,339	)
Maturities of investments		117,600				128,440
Purchases of property and equipment		(1,537	)			(1,504	)
Acquisition of business, net of cash acquired of $541		(1,773	)			—
Net cash provided by investing activities		16,259				8,597
Cash flows from financing activities:
Proceeds from exercise of stock options		417				1,379
Proceeds from issuance of common stock under employee stock purchase plan		134				265
Net cash provided by financing activities		551				1,644
Net decrease in cash and cash equivalents		(14,911	)			(9,548	)
Cash and cash equivalents, beginning of period		27,884				46,506
Cash and cash equivalents, end of period	$	12,973			$	36,958

Unaudited Reconciliation of Net Loss to EBITDA (in thousands) (Unaudited)
	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2025				2024				2025				2024
(in thousands)
Net loss	$	(12,416	)		$	(11,557	)		$	(35,034	)		$	(30,458	)
Depreciation and amortization expense		1,072				1,066				3,268				3,258
Interest income		(1,733	)			(2,496	)			(5,637	)			(7,838	)
Income taxes		—				—				—				—
EBITDA	$	(13,077	)		$	(12,987	)		$	(37,403	)		$	(35,038	)
Restructuring expense		3,058				—				3,058				—
Adjusted EBITDA	$	(10,019	)		$	(12,987	)		$	(34,345	)		$	(35,038	)

Unaudited Reconciliation of Gross Margin to Non-GAAP Adjusted gross margin (in thousands, except for percentages) (Unaudited)
	Three months ended September 30, 2025												Three months ended September 30, 2024
	GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Revenue	$	6,829			$	(423	)		$	6,406			$	8,164			$	(24	)		$	8,140
Cost of Goods Sold		1,596				(360	)			1,236				1,928				(697	)			1,231
Gross Margin		5,233				(63	)			5,170				6,236				673				6,909
Gross Margin %		77	%							81	%			76	%							85	%

	Nine months ended September 30, 2025												Nine months ended September 30, 2024
	GAAP				Adjustments				Non-GAAP				GAAP				Adjustments				Non-GAAP
Revenue	$	25,726			$	(2,878	)		$	22,848			$	29,934			$	(6,032	)		$	23,902
Cost of Goods Sold		4,612				(525	)			4,087				4,819				(834	)			3,985
Gross Margin		21,114				(2,353	)			18,761				25,115				(5,198	)			19,917
Gross Margin %		82	%							82	%			84	%							83	%

(1) Adjustments include the exclusion of SPL program related revenue from Revenue, and the exclusion of reserves for excess and obsolete inventory from Cost of Goods Sold.

FAQ

What were MaxCyte (MXCT) Q3 2025 total and core revenues?

Q3 2025 total revenue was $6.8M; core revenue was $6.4M.

How did MaxCyte (MXCT) earnings change in Q3 2025 versus Q3 2024?

Q3 2025 net loss was $12.4M versus a $11.6M loss in Q3 2024; adjusted EBITDA loss improved to $10.0M.

What guidance did MaxCyte (MXCT) give for full-year 2025 revenue?

MaxCyte reiterated core revenue guidance of flat to -10% vs 2024 and ~$5M SPL program revenue for 2025.

How much cash did MaxCyte (MXCT) report and what is year-end cash guidance?

MaxCyte had $158.0M in cash and investments on Sep 30, 2025, and expects $152M–$155M at year-end.

Did MaxCyte (MXCT) add new SPL clients in 2025 and how many agreements exist?

Yes; MaxCyte added Moonlight Bio in October and reported a total of 32 SPL agreements.

What happened to MaxCyte (MXCT) gross margins in Q3 2025?

Reported gross margin was 77%; non-GAAP adjusted gross margin declined to 81% from 85% in Q3 2024.